COMPANY

WinSanTor

HQ: San Diego, CA source · winsantor.com ↗ · West Coast

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Chemotherapy-induced Peripheral Neuropathy diabetic neuropathy Painful Diabetic Neuropathy HIV Associated Polyneuropathy Diabetes Mellitus Peripheral Neuropathy Painful Diabetic Neuropathies neuropathic pain WST-057

4Trials (company is sponsor)16NIH grants

Timeline

Nov 22, 2022 Trial start Phase 2: A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy source ↗
Feb 24, 2022 Trial start Phase 2: A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV source ↗
Nov 20, 2020 Trial start Phase 2: A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy source ↗
Oct 15, 2019 Trial start Phase 2: A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT05488873	A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy	Phase 2	Unknown status (ClinicalTrials.gov)	Nov 22, 2022	Apr 26, 2026 (estimated)
NCT05005078	A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV	Phase 2	Completed	Feb 24, 2022	Jan 18, 2023 (actual)
NCT04786340	A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy	Phase 2	Completed	Nov 20, 2020	Dec 8, 2022 (actual)
NCT04005287	A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy	Phase 2	Completed	Oct 15, 2019	Dec 15, 2021 (actual)

NIH awards 16

Annual award amounts. Total $12.0M.

Aug 23, 2022 NIH award 5R44CA265565-02 FY2022: $898,634 awarded for that fiscal year; activity R44 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Clinical investigation of topical delivery of a m source ↗
Sep 1, 2021 NIH award 1R44CA265565-01 FY2021: $1,101,366 awarded for that fiscal year; activity R44 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Clinical investigation of topical delivery of a source ↗
Mar 30, 2021 NIH award 5R44DK104512-07 FY2021: $985,495 awarded for that fiscal year; activity R44 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Regeneration of Epidermal Nerves in Human Diabeti source ↗
Sep 23, 2020 NIH award 1R41NS120354-01 FY2020: $699,491 awarded for that fiscal year; activity R41 (STTR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Development of a topical fixed-dose combination d source ↗
Jul 15, 2020 NIH award 2SB1CA213555-04 FY2020: $250,000 awarded for that fiscal year; activity SB1 (SBIR); PI MIZISIN, ANDREW; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Submission of Investigational New Drug applicati source ↗
May 8, 2020 NIH award 5R44DK104512-06 FY2020: $995,582 awarded for that fiscal year; activity R44 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Regeneration of Epidermal Nerves in Human Diabeti source ↗
Aug 9, 2019 NIH award 5R42CA213555-03 FY2019: $1,373,465 awarded for that fiscal year; activity R42 (STTR); PI MIZISIN, ANDREW; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Development of Pirenzepine for CIPN source ↗
Apr 26, 2019 NIH award 2R44DK104512-05 FY2019: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Regeneration of Epidermal Nerves in Human Diabe source ↗
Sep 20, 2018 NIH award 2R42CA213555-02 FY2018: $623,955 awarded for that fiscal year; activity R42 (STTR); PI MIZISIN, ANDREW; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Development of Pirenzepine for CIPN source ↗
Sep 18, 2017 NIH award 1R41NS105177-01 FY2017: $466,421 awarded for that fiscal year; activity R41 (STTR); PI MIZISIN, ANDREW; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Development of Pirenzepine for HIV-SN source ↗
May 23, 2017 NIH award 1R41CA213555-01A1 FY2017: $298,550 awarded for that fiscal year; activity R41 (STTR); PI MIZISIN, ANDREW; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Development of Pirenzepine for CIPN source ↗
Apr 12, 2017 NIH award 2SB1DK104512-04 FY2017: $970,226 awarded for that fiscal year; activity SB1 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Assessment of chronic toxicity to support the use source ↗
Jul 1, 2016 NIH award 5R44DK104512-03 FY2016: $591,725 awarded for that fiscal year; activity R44 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Pre-Clinical Development of Topical Pirenzepine f source ↗
Apr 4, 2016 NIH award 3R44DK104512-02S1 FY2016: $300,000 awarded for that fiscal year; activity R44 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Pre-Clinical Development of Topical Pirenzepine source ↗
Jun 24, 2015 NIH award 4R44DK104512-02 FY2015: $986,763 awarded for that fiscal year; activity R44 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Pre-Clinical Development of Topical Pirenzepine f source ↗
Sep 23, 2014 NIH award 1R44DK104512-01 FY2014: $473,338 awarded for that fiscal year; activity R44 (SBIR); PI HANSEN, ANGELA; recipient as written: WINSANTOR, INC., SAN DIEGO, CA. Pre-Clinical Development of Topical Pirenzepine f source ↗